Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin for Opioid Use Disorder
NCT03143855Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lorcaserin in opioid use disorder (OUD) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale at 5 days. Started Jan 2017; status: completed.
02
Drugs
lorcaserin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03143855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143855.